Sign in Subscribe
Health care industry

Health Professionals Inc. Announces Research Agreements with Pharmaceutical Companies

Strategic Insights

— 1 min read

Health Professionals Inc., a health care delivery system, has announced that its principal subsidiary, Center for Special Immunology Inc., has signed research agreements with two major pharmaceutical companies to participate in HIV clinical trials. The contracts, valued at $550,000 and $500,000 respectively, will support studies on protease inhibitors and thalidomide for HIV-related wasting syndrome. These trials will be conducted through CSI Clinical Trials Inc., a subsidiary responsible for conducting pharmaceutical and biotechnology research trials in collaboration with CSI's established clinical network.

Key Takeaways:

  • Health Professionals Inc. has signed research agreements with two pharmaceutical companies, a major pharmaceutical company and Celgene Corp., a biotechnology company, to participate in two HIV clinical trials.
  • The contract values of the new study agreements are $550,000 and $500,000 respectively, and will support studies on protease inhibitors and thalidomide for HIV-related wasting syndrome.
  • The trials will be conducted through CSI Clinical Trials Inc., a subsidiary responsible for conducting pharmaceutical and biotechnology research trials in collaboration with CSI's established clinical network.
  • The CSI clinical network has recently been expanded to include additional sites, with continued growth in progress.
  • The Phase II 18-month protease inhibitor study will evaluate the safety and efficacy of this protease inhibitor when given alone or in combination with AZT.
  • The Phase II trial of thalidomide will study the safety and efficacy of this drug in reducing weight loss in adults with HIV wasting syndrome.
  • CSI sites in Irvine, San Diego, Fort Lauderdale, and Kansas City will participate in the protease inhibitor study, while sites in New York, Tulsa, Kansas City, and Fort Lauderdale will participate in the thalidomide trial.
  • Health Professionals Inc. owns and operates an integrated health care delivery system that includes a multi-state network of primary care and clinical research facilities specializing in immune system disorders primarily HIV, AIDS, and Chronic Fatigue Immune Dysfunction Syndrome (CFIDS).

Statistics:

  • $550,000: contract value of the new study agreement with the major pharmaceutical company
  • $500,000: contract value of the new study agreement with Celgene Corp.
  • 18 months: duration of the Phase II protease inhibitor study
  • 2 years: duration of the study agreement with the major pharmaceutical company
  • 1 year: duration of the study agreement with Celgene Corp.

Sources:

  • Business Wire (May 12, 1995)
  • Health Professionals Inc. press release

Read more